Zephyrnet Logo

Patent Specification Concerns Make IPRs Tricky For Drug Cos.

Date:

By Dani Kass (January 28, 2022, 8:46 PM EST) — Attorneys on both sides of drug patent challenges at the Patent Trial and Appeal Board have to be extremely cautious to draft an obvious argument in a way that doesn’t undermine one for written description or enablement, according to an IPWatchdog panel.

While inter partes reviews involve only challenges based on obviousness — under Section 103 of the Patent Act — or anticipation, attorneys said arguments in the case have a high potential to hurt challenges in district courts or the U.S. International Trade Commission based on Section 112. The latter section deals with whether the patent’s specification sufficiently describes what…

spot_img

Latest Intelligence

spot_img